GDM

GDM
Name	GDM
Field	Obstetrics and Endocrinology
Synonyms	Gestational glucose intolerance
Symptoms	Hyperglycemia during pregnancy, polyuria, polydipsia, fatigue
Complications	Preeclampsia, macrosomia, neonatal hypoglycemia, type 2 diabetes
Onset	Second to third trimester
Diagnosis	Oral glucose tolerance test, fasting plasma glucose

GDM is a condition of glucose intolerance first recognized during pregnancy, characterized by elevated blood glucose levels with onset in the second or third trimester. It is managed at the intersection of Obstetrics and Endocrinology and has implications for short‑term perinatal outcomes and long‑term metabolic risk for both parent and offspring. Clinical practice draws on guidelines and research from organizations such as the World Health Organization, American College of Obstetricians and Gynecologists, and International Association of Diabetes and Pregnancy Study Groups.

Definition and overview

GDM denotes hyperglycemia first detected in pregnancy that does not meet criteria for overt diabetes as defined by American Diabetes Association or World Health Organization thresholds. Diagnostic frameworks have evolved through consensus statements from entities including International Federation of Gynecology and Obstetrics, National Institute for Health and Care Excellence, and regional bodies like Centers for Disease Control and Prevention. The condition is distinct from preexisting diabetes mellitus, which is identified by historic records, early pregnancy testing, or marked hyperglycemia meeting nonpregnancy diagnostic cutoffs endorsed by European Association for the Study of Diabetes.

Epidemiology and risk factors

Prevalence estimates vary widely, reported by surveillance systems such as National Health Service (England) datasets, CDC surveillance, and population studies from Australia, India, China, and Brazil. Rates reflect diagnostic criteria used by authorities like IADPSG and national health ministries; contemporary estimates range from low single digits to over 20% in high‑risk cohorts. Recognized risk factors include advanced maternal age (e.g., women represented in datasets from United States, Japan, Germany), prior gestational hyperglycemia documented in registries from Sweden and Norway, family history of Type 2 diabetes mellitus (as studied by Framingham Heart Study investigators), high prepregnancy body mass index noted in cohorts from United Kingdom and Canada, and certain ethnicities such as South Asian, Hispanic, and Indigenous populations described in research from India, Mexico, and Australia.

Pathophysiology and diagnosis

Pathophysiology involves pregnancy‑related insulin resistance mediated by placental hormones including human placental lactogen described in reviews from Harvard Medical School and inflammatory pathways studied at centers like Mayo Clinic and Karolinska Institute. Beta cell dysfunction unmasked by increased insulin demand leads to hyperglycemia, a mechanism examined in cohort analyses from Boston and Toronto. Diagnostic testing protocols include one‑step 75‑g oral glucose tolerance tests endorsed by IADPSG and two‑step 50‑g screening followed by 100‑g diagnostic testing used in guidance from ACOG and some national bodies. Biomarkers such as fasting plasma glucose and HbA1c are referenced in guidelines from ADA and population surveys conducted by WHO; imaging and fetal surveillance practices draw on standards from Royal College of Obstetricians and Gynaecologists.

Management and treatment

Management pathways prioritize glycemic targets and multidisciplinary care involving clinicians associated with ACOG, Endocrine Society, and local maternity services like NHS England. First‑line therapy emphasizes lifestyle modification—medical nutrition therapy and physical activity—supported by evidence from randomized trials at institutions such as Johns Hopkins Medicine and Cochrane. When glycemic targets are not met, pharmacologic options include insulin regimens informed by protocols from Diabetes UK and oral agents like metformin and glyburide evaluated in trials from University of Auckland and University of Toronto. Antepartum fetal monitoring, timing of delivery, and intrapartum glucose management follow recommendations from Society for Maternal‑Fetal Medicine and national obstetric colleges, with coordination for neonatal care per standards from American Academy of Pediatrics.

Outcomes and complications

Short‑term maternal complications include increased risk of hypertensive disorders of pregnancy such as preeclampsia, described in cohort studies from Norway and Finland. Fetal and neonatal risks include macrosomia, shoulder dystocia, and neonatal hypoglycemia documented in perinatal registries from United States and Australia. Longitudinal studies from centers like Harvard and Imperial College London show elevated lifetime risk of Type 2 diabetes mellitus and cardiovascular disease for parents, and heightened risk of obesity and impaired glucose tolerance in offspring, as observed in birth cohort studies from Pune and Avon Longitudinal Study of Parents and Children. Health systems such as Medicare and national insurance programs monitor economic and service burdens associated with GDM care.

Prevention and screening strategies

Prevention strategies evaluated in randomized trials from Diabetes Prevention Program investigators and trials in Finland focus on weight management, physical activity, and preconception counseling provided by services like Planned Parenthood and primary care networks. Screening approaches vary: universal screening at 24–28 weeks is recommended by organizations including IADPSG and WHO, while risk‑based screening is endorsed in some guidance from NICE and national societies. Preconception identification of high‑risk individuals using family history captured in primary care records and targeted interventions informed by research from Massachusetts General Hospital aim to reduce incidence and improve outcomes.

Category:Pregnancy-related disorders